Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

Loading...
Thumbnail Image

Date

2012-10-23

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

120
views
111
downloads

Citation Stats

Attention Stats

Abstract

BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries. METHODS: We analysed outcome among all patients (n=99) who received subsequent therapy after progression on one of five consecutive, single-arm, phase II clinical trials evaluating bevacizumab regimens for recurrent glioblastoma. Of note, the five trials contained similar eligibility, treatment and assessment criteria, and achieved comparable outcome. RESULTS: The median overall survival (OS) and OS at 6 months for patients who continued bevacizumab therapy (n=55) were 5.9 months (95% confidence interval (CI): 4.4, 7.6) and 49.2% (95% CI: 35.2, 61.8), compared with 4.0 months (95% CI: 2.1, 5.4) and 29.5% (95% CI: 17.0, 43.2) for patients treated with a non-bevacizumab regimen (n=44; P=0.014). Bevacizumab continuation was an independent predictor of improved OS (hazard ratio=0.64; P=0.04). CONCLUSION: The results of our retrospective pooled analysis suggest that bevacizumab continuation beyond initial progression modestly improves survival compared with available non-bevacizumab therapy for recurrent glioblastoma patients require evaluation in an appropriately randomised, prospective trial.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1038/bjc.2012.415

Publication Info

Reardon, DA, JE Herndon, KB Peters, A Desjardins, A Coan, E Lou, AL Sumrall, S Turner, et al. (2012). Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer, 107(9). pp. 1481–1487. 10.1038/bjc.2012.415 Retrieved from https://hdl.handle.net/10161/16115.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Desjardins

Annick Desjardins

Professor of Neurosurgery

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.